Chronic Myeloid Leukemia with Increased Granulocyte Progenitors in Mice Lacking JunB Expression in the Myeloid Lineage  by Passegué, Emmanuelle et al.
Cell, Vol. 104, 21–32, January 12, 2001, Copyright ª 2001 by Cell Press
Chronic Myeloid Leukemia with Increased
Granulocyte Progenitors in Mice Lacking JunB
Expression in the Myeloid Lineage
tified, such as Pu.1 and the CCAAT/enhancer binding
proteins c/EBPa and c/EBPe (reviewed in Tenen et al.,
1997). However, little is known about transcription fac-
tors that modulate cell numbers in the myeloid lineage
by controlling cell proliferation and cell death.
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A-1030 Vienna JunB is a component of the AP-1 (Activator Protein-1)
transcription factor, a collection of dimeric complexesAustria
†Deutsches Krebsforschungszentrum Heidelberg composed of proteins of the Jun (c-Jun, JunB, JunD),
Fos (c-Fos, FosB, Fra-1, Fra-2), and ATF families, which(DKFZ)
Division of Signal Transduction and Growth Control convert extracellular signals into changes in the tran-
scription of specific target genes (Angel and Karin,Im Neuenheimer Feld 280
D-69120 Heidelberg 1991). Analysis in mice and in tissue culture cells have
indicated that each AP-1 member may have distinctGermany
biological functions by regulating particular subsets of
target genes in a cell-type specific fashion (reviewed in
Karin et al., 1997). Based mainly on in vitro results, JunBSummary
has initially been suggested to function as a general
repressor of AP-1-mediated transactivation (Chiu et al.,The functions of JunB during myelopoiesis were stud-
1989). However, more recent studies have demon-ied in vivo. Transgenic mice specifically lacking JunB
strated that JunB may also selectively regulate tran-expression in the myeloid lineage (junB2/2Ubi-junB
scription, both in a positive or negative manner, de-mice) develop a transplantable myeloproliferative dis-
pending on the interacting partner and the promoterease eventually progressing to blast crisis, which re-
context (Hsu et al., 1993). Inactivation of junB in micesembles human chronic myeloid leukemia. Similarly,
results in vascular defects leading to early lethalitymice reconstituted with ES cell-derived junB2/2 fetal
(Schorpp-Kistner et al., 1999). In contrast, constitutiveliver cells also develop a myeloproliferative disease.
JunB overexpression from the human ubiquitin C pro-In both cases, the absence of JunB expression results
moter has no major consequences in Ubi-junB trans-in increased numbers of granulocyte progenitors,
genic mice (Schorpp et al., 1996), although proliferationwhich display enhanced GM-CSF-mediated prolifera-
of transgenic fibroblasts is strongly impaired (Passegue´tion and extended survival, associated with changes
and Wagner, 2000). Moreover, the recent demonstrationin the expression levels of the GM-CSFa receptor, the
that JunB directly activates the cyclin-dependent kinaseanti-apoptotic proteins Bcl2 and Bclx, and the cell cy-
inhibitor p16INK4a and inhibits cyclin D1, has clearly estab-cle regulators p16INK4a and c-Jun. Importantly, ectopic
lished that JunB functions as a negative regulator of cellexpression of JunB fully reverts the immature and hy-
proliferation (Bakiri et al., 2000; Passegue´ and Wagner,perproliferative phenotype of JunB-deficient myeloid
2000). In addition, JunB has recently been shown tocells. These results identify JunB as a key transcrip-
control cytokine-regulated mesenchymal–epidermal in-tional regulator of myelopoiesis and a potential tumor
teractions in the skin (Szabowski et al., 2000).suppressor gene.
JunB is constitutively expressed in human mature
granulocytes and its expression is strongly induced fol-Introduction
lowing terminal differentiation of bone marrow myeloid
precursors and established myeloid cell lines (MollinedoMyelopoiesis, the highly regulated process that pro-
et al., 1991; Lord et al., 1993). Furthermore, JunB hasduces granulocytes and monocytes, depends on the
been isolated in a screen for myeloid differentiation pri-coordinated proliferation, survival, and differentiation of
mary response genes (Liebermann and Hoffman, 1998).hematopoietic stem cells and committed myeloid pro-
It was, therefore, suggested that JunB may have a rolegenitors. Distortion of any of these cellular functions
in the initiation, the progression, or the maintenanceis potentially tumorigenic and may result in leukemia.
of the myeloid differentiation program, but its specificGrowth factors and cytokines, including interleukin-3
functions have not yet been identified. Here, we have(IL-3) and granulocyte/macrophage colony-stimulating
used in vivo approaches with junB2/2Ubi-junB trans-factor (GM-CSF), control myelopoiesis by promoting
genic mice and junB2/2 cells to investigate the functionssurvival, proliferation, and/or differentiation of particular
of JunB during myelopoiesis.subsets of cells expressing their specific receptors (re-
viewed in Bagley et al., 1997). Recently, transcriptional
Resultsregulators critical for both early myeloid commitment
and terminal granulocyte differentiation have been iden-
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Figure 1. Adult junB2/2Ubi-junB Mice Develop a Myeloproliferative Disease with Progression to Blast Crisis
(A–G) Myeloproliferative disease in junB2/2Ubi-junB mice. Massive enlargement of the spleen (A) and lymph nodes (B) from a 7-month-old
diseased junB2/2Ubi-junB mouse (right) compared to an age-matched wild-type control (left). (C) Abnormal chloroacetate esterase (CAE)
staining in the periportal areas of the liver. (D) May-Gru¨nwald-Giemsa stained blood smear showing increased numbers of segmented
neutrophils (arrowhead) in the peripheral blood. (E) Percentage of Gr-1hi/Mac-1hi granulocytes in spleen, bone marrow, and lymph nodes of
1-month-old (n 5 2), 4- to 6-month-old (n 5 6), and 7- to 11-month-old (n 5 7) mice. (F) Flow cytometric analysis of cells from the spleen
(Sp), bone marrow (BM), and thymus (Th) from 8-month-old mice. (G) May-Gru¨nwald-Giemsa stained cytospins of splenocytes from 8-month-
old mice. (H) Blast crisis in junB2/2Ubi-junB mice. Histological examination of nonhematopoietic organs such as lung and heart indicates a
massive infiltration by blast cells (stars). For comparison wild-type tissues are shown in the inserts. Analysis by CAE staining and MPO
immunohistochemistry of a blast-infiltrated kidney (Kid) showing focal areas of myeloid differentiation.
junB mice developed a myeloproliferative disease with numbers in the peripheral blood were 3-fold increased
at 3–4 months of age and reached a 10-fold increase bycomplete penetrance by 11 months of age (Figure 1).
Upon necropsy, 7- to 11-month-old diseased junB2/2Ubi- 6–11 months (Table 1). Differential blood counts indicated
elevated numbers of mature neutrophilic granulocytesjunB mice consistently showed a massive enlargement
of spleen, lymph nodes, and liver (Figures 1A–1C). Histo- (Figure 1D), but comparable numbers of eosinophilic gran-
ulocytes, erythrocytes, and monocytes. Furthermore, im-logical and cytological examination of these organs re-
vealed increased cellularity and a pronounced infiltra- munohistochemistry for the macrophage marker F4/80
also indicated similar numbers of tissue macrophagestion by cells positively stained for the myeloid marker
chloroacetate esterase (CAE; Figure 1C). The leukocyte (data not shown). In contrast, none of the wild-type or
JunB Functions during Myelopoiesis
23
Table 1. Peripheral Blood Counts
3–4 Months 6–11 Months
junB1/1 junB1/1Ubi-junB junB2/2Ubi-junB junB1/1 junB1/1Ubi-junB junB2/2Ubi-junB
(n 5 5) (n 5 7) (n 5 11) (n 5 8) (n 5 10) (n 5 11)
Leukocytes/ml (3 103) 5.0 6 0.4 5.3 6 0.8 17.7 6 6.8b 4.9 6 0.6 6.9 6 1.3 52.6 6 9.9b
Erythrocytes/ml (3 106) 8.9 6 0.2 9.6 6 0.2 8.8 6 0.8 8.9 6 0.2 9.5 6 0.3 9.0 6 0.6
Platelets/ml (3 105) 750 6 28 783 6 52 870 6 93 1011 6 75 1052 6 88 1139 6 155
Neutrophil segmentsa 26.9 6 4.3 21.6 6 2.9 46.3 6 5.4b 29.8 6 3.5 26.5 6 2.0 72.2 6 3.0b
Neutrophil bandsa 0.9 6 0.2 1.0 6 0.2 1.6 6 0.2c 0.5 6 0.1 0.8 6 0.2 2.8 6 0.4b
Lymphocytesa 68.0 6 5.1 70.9 6 2.8 45.2 6 5.3b 64.1 6 3.7 67.1 6 2.0 17.9 6 2.5b
Eosinophilsa 2.6 6 0.4 2.9 6 0.5 2.8 6 0.5 3.3 6 0.6 2.7 6 0.4 3.2 6 0.9
Monocytesa 2.3 6 0.5 3.5 6 0.5 3.3 6 0.5 2.2 6 0.4 2.9 6 0.3 2.2 6 0.4
Results are mean (6 SD) of the indicated numbers of mice. a percentage of cells determined by differential counts on 300 cells per blood
smear. b p # 0.001. c p # 0.005.
junB1/2 mice, either with or without the Ubi-junB trans- constituted with bone marrow cells from control and
junB2/2Ubi-junB mice at various stages of disease pro-gene, showed any evidence of increased myelopoiesis
(Table 1; data not shown) and were, therefore, collec- gression (Table 2). Analysis of recipient-derived bone
marrow and spleen DNA indicated full reconstitution bytively used as controls. Flow cytometric analysis and
cytological investigations further confirmed the age-de- donor cells (data not shown). Within 15 months after
transplantation, all recipients reconstituted with junB2/2pendent increase in Gr-1hi/Mac-1hi granulocyte numbers
in spleen, bone marrow, and lymph nodes of junB2/2Ubi- Ubi-junB bone marrow cells developed elevated neutro-
phil counts in the peripheral blood, increased numbersjunB mice (Figures 1E–1G). Conversely, a relative de-
crease in the numbers of B and T cells was observed of Gr-1hi/Mac-1hi granulocytes in the spleen and bone
marrow, and prominent myeloid hyperplasia in thein mutant spleen and bone marrow, although the total
numbers of lymphocytes appeared comparable to con- spleen. Interestingly, the onset of the disease was de-
pendent on the age of the junB2/2Ubi-junB donor cells.trol when corrected for the increased cellularity. Further-
more, analysis of mutant thymi indicated similar num- Myeloid hyperplasia occurred 2 months after reconstitu-
tion with cells from 12-month-old donors, but requiredbers of single and double positive CD4 and CD8 T
lymphocytes (Figure 1F). Together, these results indi- 6 to 9 months with cells from 6- to 7-month-old donors
and on average 12 months with cells from 1-month-cate that junB2/2Ubi-junB mice develop a progressive
myeloid hyperplasia with overproduction of mature neu- old donors. Secondary transplantation of mutant bone
marrow cells also resulted in a myeloproliferative dis-trophilic granulocytes.
Furthermore, in 3 out of 19 junB2/2Ubi-junB mice ease within 2–5 months after reconstitution (data not
shown). In contrast, none of the recipients reconstituted(16%), histological analysis revealed a massive blast cell
infiltration of nonhematopoietic organs such as lung, with control bone marrow cells showed any evidence
of increased myelopoiesis for up to 15 months afterheart, and kidney (Figure 1H). Since CAE staining and
myeloperoxidase (MPO) immunohistochemistry only transplantation. These results therefore demonstrate
that the myeloproliferative disease in junB2/2Ubi-junBshowed focal areas of positivity in 1 out of 3 blast-
infiltrated kidneys, the majority of the blast cells ap- mice is fully transplantable.
peared undifferentiated. These results indicate that the
myeloproliferative disease in junB2/2Ubi-junB mice can Loss of Ubi-junB Transgene Expression
in junB2/2Ubi-junB Myeloid Cellsprogress to blast crisis, thereby recapitulating the natu-
ral course of human chronic myeloid leukemia (CML). To investigate the correlation between JunB levels and
the myeloproliferative disease, expression of the endog-
enous junB gene and the Ubi-junB transgene was ana-The Increased Myelopoiesis in junB2/2Ubi-junB
Mice Is Cell Autonomous lyzed by RT-PCR and Western blot in different hema-
topoietic compartments of 9-month-old control andTo test whether the myeloproliferative disease is cell-
autonomous, lethally irradiated wild-type mice were re- diseased junB2/2Ubi-junB mice (Figure 2). In wild-type
Table 2. Transplantable Myeloproliferative Disease
Donor Age Number Number Observation Myeloid % Gr-1hi/Mac-1hi
(Months) of Donors of Recipients Time (Months) Hyperplasia Granulocytes
Control 1–12 5 10 2–15 0/10 49.4 6 5.3
junB2/2Ubi-junB 1 2 3 2–15 3/3 69.7 6 3.2
6–7 3 8 2–11 8/8 79.1 6 7.8
12 2 3 2 3/3 83.0 6 5.7
Lethally irradiated wild-type mice were injected IV with 2 3 106 bone marrow cells from control or junB2/2Ubi-junB donor mice of the indicated
age. Recipient mice were monitored monthly by blood smears and scored positive for myeloproliferative disease when neutrophilic blood
counts were above 50%. Recipient mice were further analyzed by histology for myeloid hyperplasia in the spleen and by flow cytometry to
determine the percentage of Gr-1hi/Mac-1hi granulocytes in the bone marrow.
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mice, endogenous junB mRNA was expressed, although
at different levels, in all hematopoietic lineages includ-
ing granulocytes (Figure 2A). In junB2/2Ubi-junB mice,
transgenic Ubi-junB mRNA was detected in B and T cells
and erythrocytes but not in granulocytes. Furthermore,
whereas in B lymphocytes the Ubi-junB transgene re-
stored JunB protein levels to almost wild-type levels,
no JunB protein was detected in granulocytes (Figure
2B). To determine whether the Ubi-junB transgene was
expressed at any level in the myeloid lineage, granu-
locytes were isolated from junB2/2Ubi-junB mice at
various ages and analyzed by RT-PCR. Interestingly,
Ubi-junB transgene expression was detected in granulo-
cytes of 1-month-old mice and of 4- to 6-month-old mice
that did not yet show any signs of the myeloproliferative
disease (Figure 2C). However, a massive reduction or
complete loss of Ubi-junB transgene expression was
observed in all diseased junB2/2Ubi-junB mice investi-
gated between 4 and 12 months of age (n 5 9). In con-
trast, the transgene was stably expressed in purified B
lymphocytes from all tested mice. Southern blot analysis
of DNA extracted from granulocytes of junB2/2Ubi-junB
mice lacking transgene expression did not reveal major
changes in the integration site nor in the copy number
of the transgene (Figure 2D). These results indicate that
the development of the myeloproliferative disease coin-
cides with an age-dependent and myeloid-specific si-
lencing of the Ubi-junB transgene.
The Absence of junB Expression in ES Cells
Results in Increased Myelopoiesis In Vitro
and a Myeloproliferative Disease In Vivo
An independent experimental approach was used to
confirm the strict correlation between absence of JunB
and altered myelopoiesis. Thus, genetically defined mu-
tant junB2/2 and control junB1/2 embryonic stem (ES)
cells were differentiated into myeloid cells in vitro (Fig-
ures 3A–3C). Embryoid bodies (EBs) were first gener-
ated and EBs-derived cells were subsequently grown
in conditions promoting myeloid cell differentiation. EBs
of both genotypes contained mainly immature cells
(Sca-1hi, CD34lo-hiand c-Kithi) and erythroid cells (Ter119hi;
Figures 3A and 3B). After 19 and 21 days, differentiated
myeloid cells could be observed in EBs-derived colonies
of both genotypes (Figure 3C). However, colonies de-Figure 2. Myeloid Cells from Diseased junB2/2Ubi-junB Mice Fail
to Express the Ubi-junB Transgene rived from junB2/2 ES cells contained more cells carrying
myeloid markers, including numerous Gr-1hi/Mac-1hiSplenocytes from 9-month-old control and diseased junB2/2Ubi-
junB mice were separated by flow cytometry into CD4hi/CD8lo T granulocytes corresponding to mature segmented neu-
helper cells (T), CD19hi/IgMhi B lymphocytes (B), Ter119hi erythroid trophils (Figures 3A–3C). Conversely, a relative decrease
cells (E), and Gr-1hi/Mac-1hi granulocytes (G) and analyzed for the in the numbers of immature c-Kit and CD34 expressing
expression of the endogenous junB gene and the Ubi-junB trans-
cells was observed while no differences were found ingene by RT-PCR (A) and Western blot (B). RNAs from wild-type,
the numbers of Ter119hi erythroid cells. These resultsUbi-junB transgenic, and junB2/2 fibroblasts were used as controls
for the RT-PCR and tubulin expression and actin protein levels were indicate that the absence of junB expression enhances
used as loading controls. (C) Correlation between the age-depen- differentiation along the granulocytic lineage without af-
dent loss of Ubi-junB transgene expression in the myeloid lineage fecting other lineages.
and the development of the myeloproliferative disease. Splenic
granulocytes and B lymphocytes were isolated by flow cytometry
from junB2/2Ubi-junB mice at the indicated ages and analyzed by
RT-PCR for Ubi-junB transgene expression. Mice scored positive
press the Ubi-junB transgene. DNAs extracted from the kidneys of(1) for the myeloproliferative disease displayed splenomegaly and
more than 70% granulocytes in the bone marrow. (D) Southern blot wild-type mice are shown for comparison (BamH1-digested DNA
hybridized with a SmaI/DraI junB cDNA probe recognizing the en-analysis of DNA extracted from kidney (kid) and purified splenic
granulocytes (G) and B lymphocytes (B) from two independent 7- to dogenous (endo) junB gene, the Ubi-junB transgene (tg), and the
knockout (ko) junB allele).12-month-old diseased junB2/2Ubi-junB mice, which did not ex-
JunB Functions during Myelopoiesis
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Figure 3. Absence of JunB Enhances Myeloid Differentiation In Vitro and Leads to Myeloid Hyperplasia In Vivo
(A–C) Enhanced myeloid differentiation in junB2/2 ES cells in vitro. (A) Flow cytometric analysis of differentiated EBs (day 6) and EB-derived
hematopoietic colonies (days 19 and 21) obtained from junB2/2 and junB1/2 ES cells. (B) Quantification of positive cells for each marker used.
Results are the mean (6 SD) of two independent cultures per genotype. (C) May-Gru¨nwald-Giemsa stained cytospins of EB-derived hematopoi-
etic colonies (day 21) confirming the elevated numbers of segmented neutrophils (arrowhead) in junB2/2-derived cultures. (D–F) Transplantation
of junB2/2 ES cell-derived fetal liver cells causes a myeloproliferative disease in vivo. (D) PCR genotyping of cells from spleen (Sp), bone
marrow (BM), thymus (Th), and muscle (Ms) isolated from the recipients 12 months after transplantation (wt: wild-type junB allele; ko: knockout
junB alleles). The faint wild-type band observed in hematopoietic organs of junB2/2 fetal liver transplanted mouse is due to the presence of
host-derived stromal cells. (E) May-Gru¨nwald-Giemsa stained blood smears from recipients 6 months after transplantation. (F) Flow cytometric
analysis of cells from spleen (Sp), bone marrow (BM), and thymus (Th) isolated from recipients 12 months after transplantation.
To determine whether the absence of JunB also However, within 6–9 months after transplantation, all
mice reconstituted with junB2/2 fetal liver cells (n 5causes increased myelopoiesis in vivo, lethally irradi-
ated wild-type mice were reconstituted with junB2/2 ES 5) showed a progressive increase in the numbers of
neutrophilic granulocytes in the peripheral blood (Figurecell-derived E12.5 fetal liver cells (Figures 3D–3F). Geno-
typing of cells from spleen, bone marrow, and thymus of 3E) and, by 12 months posttransplantation, displayed
a marked myeloid hyperplasia in the spleen and bonethe recipients 12 months after transplantation confirmed
the reconstitution by junB2/2 hematopoietic stem cells marrow with overproduction of Gr-1hi/Mac-1hi granulo-
cytes (Figure 3F). Furthermore, a relative decrease in(Figure 3D). Blood and flow cytometric analysis further
revealed the presence of mature myeloid, erythroid, and the number of B cells was observed in spleen and bone
marrow of recipients reconstituted with junB2/2 fetallymphocytic cells indicating the full reconstitution of all
principal hematopoietic lineages (Figures 3E and 3F). liver cells.
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Figure 4. Increased Granulocyte Progenitors in the Absence of JunB
(A) Flow cytometric analysis of propidium iodide labeled Gr-1/Mac-1 stained splenocytes from 7-month-old control and junB2/2Ubi-junB mice.
The right panels give the DNA content of the gated Gr-1hi/Mac-1hi granulocytes. (B) Colony-forming assay performed with bone marrow and
spleen cells from control and junB2/2Ubi-junB mice at the age of 4–6 months and 7–12 months. Results are the mean (6 SD) of four mice
per experimental group. (C) Colony-forming assay performed with bone marrow and spleen cells isolated from junB2/2 and junB1/1 fetal liver
transplanted mice 12 months after reconstitution. Results are the mean (6 SD) of three mice. (D–F) Primary splenocytes from 7- to 9-month-
old control and junB2/2Ubi-junB mice were used for both the colony-forming assay and the liquid culture assays performed in the presence
of the indicated growth factors, alone or in combination (Mix). (D) GM-CFU numbers and average cell numbers per colony were determined
from the same methylcellulose dish after 7 days. Results are the mean (6 SD) of three mice. (E) Cells were grown for 72 hr in liquid culture
and either pulse-labeled with 3H-thymidine for 2 hr to determine the proliferation rates, or processed for Gr-1/AnnexinV staining to determine
the percentage of apoptotic granulocytes (18: primary splenocytes). Results are the mean (6 SD) of three mice. (F) Cells were grown for 72
hr in liquid culture containing either the indicated amounts of GM-CSF or 1 ng/ml GM-CSF and 20 mg/ml GM-CSF neutralizing antibody (neut.
Ab), or the combination of all factors (Mix). Pulse-labeling was performed for 2 hr with 3H-thymidine to determine the proliferation rates.
Results are the mean (6 SD) of three mice.
Increased Numbers of Granulocyte Progenitors numbers were found in cultures of 7- to 12-month-old
control and mutant mice. In contrast, the numbers ofin the Absence of JunB
To determine whether the myeloproliferative disease GM-CFU were dramatically elevated in cultures from
junB2/2Ubi-junB splenocytes reaching an 11-fold in-arises at the progenitor level, the relative numbers of
cycling myeloid cells were quantified in vivo. In control crease by the age of 7–12 months. Together with the
histological findings, these results indicate that the my-mice, the majority of Gr-1hi/Mac-1hi cells were arrested
in the G0/G1 phase of the cell cycle with less than 1% eloid hyperplasia in the bone marrow of junB2/2Ubi-junB
mice progressively leads to extramedullary hematopoie-in the S and G2/M phase (Figure 4A). In contrast, be-
tween 10% and 15% of Gr-1hi/Mac-1hi cells from the sis in the spleen. Colony-forming assays performed with
cells from junB2/2 fetal liver transplanted mice alsojunB2/2Ubi-junB mice (n 5 5) were in the S and G2/M
phase. Increased numbers of cycling Gr-1hi/Mac-1hi cells showed increased numbers of GM-CFU (Figure 4C), but
primarily in bone marrow–derived cultures.were also observed in the bone marrow of recipients
reconstituted with junB2/2 fetal liver cells (data not
shown). Since only progenitor cells are mitotically active, Increased GM-CSF-Mediated Proliferation
and Extended Survival in JunB-Deficientthese results suggest that junB2/2Ubi-junB mice have
increased numbers of cycling granulocyte progenitors. Granulocyte Progenitors
To study the cellular mechanisms accounting for theNext, the numbers of granulocyte progenitors in the
bone marrow and spleen of junB2/2Ubi-junB mice were expansion of the granulocytic compartment, mutant and
control splenocytes were cultured in methylcellulose-quantified in vitro using colony-forming assays (Figure
4B). A less than 2-fold increase in the number of bone based media containing only a single growth factor or
cytokine (Figure 4D). After 7 days, increased GM-CFUmarrow–derived granulocyte/macrophage colony-form-
ing units (GM-CFU) was observed in cultures of 4- to numbers were observed in junB2/2Ubi-junB cultures for
all the single factors tested, e.g., IL-3, SCF, GM-CSF,6-month-old junB2/2Ubi-junB mice and comparable
JunB Functions during Myelopoiesis
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and G-CSF. Interestingly, the number of cells per colony
increased only in cultures containing GM-CSF alone or
in combination with the other factors. Next, splenocytes
were grown in liquid culture for 72 hr and pulsed for 2
hr with 3H-thymidine to determine the proliferation rates
(Figure 4E). When grown with IL-3, SCF, or G-CSF alone,
no significant differences were found between the prolif-
eration rates of control and mutant cells. In contrast,
junB2/2Ubi-junB cells showed dramatically increased
proliferation when grown in the presence of GM-CSF,
alone or in combination with the other factors. Further-
more, junB2/2Ubi-junB splenocytes displayed a faster
and stronger dose-dependent proliferative response in
response to increasing amounts of GM-CSF, an effect
that was completely abolished by cotreatment with a
GM-CSF neutralizing antibody (Figure 4F). Finally, the
fraction of apoptotic granulocytes was determined using
double Gr-1/AnnexinV staining (Figure 4E). Interestingly,
primary junB2/2Ubi-junB splenocytes already displayed
reduced numbers of Gr-1hi/AnnexinVhi apoptotic granu-
locytes compared to control cells. After 72 hr of culture,
a 30% to 50% reduction in the numbers of apoptotic
granulocytes was observed independently of the cyto-
kine or growth factor used. Mutant bone marrow cells
showed similar results in all three assays (e.g, GM-CFU,
proliferation, and apoptosis; data not shown). These
results indicate that JunB-deficient granulocyte progen-
itors have increased responsiveness to GM-CSF-medi-
ated proliferation and extended survival.
Altered Gene Expression in JunB-Deficient
Myeloid Cells
The transcriptional changes associated with the ab-
sence of JunB were analyzed by RT-PCR both in primary
splenic Gr-1hi/Mac-1hi granulocytes and in in vitro culti-
vated GM-CSF colony-forming cells (GM-CSF-CFCs)
(Figure 5A). All the populations used were tested for the
absence of contaminating cells of other hematopoietic
lineages, such as CD19 expressing B cells, and for the
absence of Ubi-junB transgene expression in junB2/2Ubi-
junB cells (data not shown). The two Gr-1hi/Mac-1hi popula-
tions, which contain mostly mature granulocytes but
also a few granulocyte and monocyte progenitors (La-
gasse and Weissman, 1996), displayed comparable ex-
pression levels of the granulocyte marker c/EBPe. In
contrast, both control and mutant GM-CSF-CFC popula-
tions, which predominantly consist of immature progeni-
tors, expressed very low levels of c/EBPe. Higher ex-
pression levels of the stem cell markers c-Kit and Pu.1
Figure 5. Altered Gene Expression in JunB-Deficient Myeloid Cellswere detected in the two different junB2/2Ubi-junB cell
types implying that JunB-deficient populations contain Primary Gr-11/Mac-11 granulocytes were purified by flow cytometry
from spleens of 7- to 9-month-old junB2/2Ubi-junB and age-increased numbers of progenitor cells. Interestingly,
matched control mice (n 5 2). GM-CSF colony-forming cells (GM-higher expression levels of the two anti-apoptotic genes
CSF-CFC) were harvested from spleen-derived methylcellulose cul-Bcl2 and Bclxl and of the receptors for GM-CSFa and
tures grown for 7 days in the presence of GM-CSF only (n 5 2).
M-CSF were also consistently detected in mutant cells. Both populations were analyzed by RT-PCR (A) and Western blot
Whereas expression of the G-CSFa receptor was com- (B) for expression levels of the indicated genes. Expression of tubulin
parable between junB2/2Ubi-junB and control primary and HPRT, coamplified with p16, were used as loading control for
the RT-PCR and actin protein levels were used as controls for thegranulocytes, its expression was absent in control GM-
Western blot.CSF-CFCs. In contrast, low levels were detected in
junB2/2Ubi-junB GM-CSF-CFCs, which further indicates
the differences between control and mutant GM-CSF- not different in any of the cell populations. JunB-defi-
cient cells also displayed the expected changes forCFCs in terms of maturation stage. Expression of the
IL-3 receptor and IL-6 receptor (data not shown) were known JunB target genes since c-Jun expression, ex-
Cell
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Figure 6. Establishment and Characterization of Bone Marrow–Derived JunB-Deficient Myeloid Mast Cells
Bone marrow–derived mast cell lines were established from 4- to 6-month-old control and junB2/2Ubi-junB mice. (A) Immortalization curves
of five clonal mast cell lines. May-Gru¨nwald-Giemsa stained cytospins showing the morphology of control M1 and JunB-deficient M3 mast
cells after 45 days of culture. (B) RT-PCR analysis of the indicated genes after 20 days of culture. (C) JunB-deficient mast cells were infected
for 3 days with an empty virus (pB-puro) or viruses expressing junB (pB-junB) or p16 (pB-p16) and grown for 6 days without puromycin
selection to determine the proliferation rate or with puromycin selection to examine marker expression (c-Kit, FceR) and apoptotic levels
(annexin V) by flow cytometry. Results are the mean (6 SD) of the two JunB-deficient cell lines.
pected to be repressed by JunB (Chiu et al., 1989), was ation phenotype and to induce terminal differentiation
of immature myeloid cells.increased and p16 expression, which has been shown
to be activated by JunB (Passegue´ and Wagner, 2000),
was decreased. Elevated Bcl2, Bclxl, and c-Jun expres- Discussion
sion in mutant primary granulocytes was further con-
firmed at the protein level (Figure 5B) while p16 expres- A variety of experimental approaches with transgenic
mice and knockout cells were used to define the func-sion was below detection levels in both control and
mutant cells (data not shown). tions of JunB during myelopoiesis. JunB2/2Ubi-junB
transgenic mice develop a transplantable myeloprolifer-
ative disease, which coincides with a myeloid-specificEctopic Expression of JunB Rescues the Phenotype
of JunB-Deficient Myeloid Cells and age-dependent loss of junB expression. In a signifi-
cant proportion of these mice (16%), the chronic myelo-Bone marrow–derived mast cell lines were isolated from
4- to 6-month-old control and junB2/2Ubi-junB mice (n 5 proliferative disease further progresses to blast crisis,
thereby recapitulating the natural course of human CML,3) to study the growth properties of JunB-deficient my-
eloid cells. Out of 39 cell lines, 12 clones (31%) were which accounts for about 25% of all adult leukemia
(reviewed in Sawyers, 1999). This disease progressionfound to have lost Ubi-junB transgene expression. Two
wild-type clones (M1, M2), two junB2/2Ubi-junB clones in two steps is consistent with the model of multistep
tumorigenesis (reviewed in Hanahan and Weinberg,lacking transgene expression (M3, M4), and one clone
expressing the transgene (M5) were established (Figures 2000) and suggests that additional genetic alterations
are necessary to fully transform JunB-deficient myeloid6A and 6B). During the first month, the proliferation rates
of all cell lines were comparable, but, thereafter, the cells. Most importantly, experiments performed with ge-
netically defined junB2/2 ES cells directly prove that thecontrol lines as well as the Ubi-junB expressing M5 line
stopped proliferating and differentiated into mature observed chronic myeloproliferative disease is caused
by the absence of JunB. In vitro, JunB-deficient ES cellsmast cells expressing low levels of c-Kit and Sca-1 but
high levels of FceR (Figure 6A and data not shown). display enhanced myeloid differentiation and in vivo
mice reconstituted with ES cell-derived junB2/2 fetalIn contrast, the two JunB-deficient lines continued to
proliferate and maintained an immature phenotype as liver cells develop a myeloid hyperplasia similar to the
one observed in junB2/2Ubi-junB mice. These resultsindicated by their morphology (Figure 6A) and their cell
surface marker expression (c-Kithi, Sca-1hi, no expres- demonstrate that JunB is a critical determinant for mye-
lopoiesis since its absence results in a myeloid leukemia.sion of FceR; data not shown). The JunB-deficient mast
cells also displayed reduced expression levels of p16 The mechanisms responsible for the loss of junB ex-
pression in junB2/2Ubi-junB mice remain largely un-and increased expression levels of c-jun and Bcl2 (Fig-
ure 6B). Retroviral introduction of JunB into JunB-defi- known, although no major rearrangements or deletions
of the Ubi-junB transgene can be detected at the DNAcient mast cells suppressed proliferation by inducing
differentiation into mature mast cells (c-Kitlo, Sca-1lo, level in cells from the myeloid lineage. Interestingly, the
Ubi-junB silencing also occurs in wild-type Ubi-junBFceRlo-hi) without changing the apoptotic levels (Figure
6C). In contrast, ectopic expression of p16 did not in- transgenic mice and appears to be independent of the
integration site since it is present in junB2/2Ubi-junBduce differentiation but led to increased cell death and
reduced proliferation. These results indicate that ex- mice obtained with a second Ubi-junB founder line (data
not shown). We are currently investigating whether thepression of JunB is sufficient to fully reverse the prolifer-
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transcriptional silencing of the human ubiquitin C pro-
moter could be due to cell-type specific epigenetic mod-
ifications, such as deacetylation or DNA methylation.
Our results demonstrate that JunB functions during
myelopoiesis are to control the numbers of granulocyte
progenitors without interfering with granulocyte matura-
tion. It is also important to note that the absence of
JunB does not change the numbers of monocytes and
macrophages in vivo although JunB-deficient granulo-
cytes display elevated levels of the M-CSF receptor and
show increased proliferation in response to recombinant
M-CSF in vitro (data not shown). Therefore, JunB seems
to be selectively required during late stages of granulo-
poiesis, most likely after the divergence from the mono-
cytic pathway. JunB is present in mature granulocytes
(Lord et al., 1993), but nothing is known about its expres-
sion during the different stages of myeloid differentia-
tion. Furthermore, JunB expression is modulated by var-
Figure 7. JunB Functions during Myelopoiesisious growth factor signaling cascades that are broad
JunB acts during late granulopoiesis by controlling the numbersregulators of proliferation, differentiation, and/or sur-
of granulocyte progenitors through inhibition of proliferation andvival in the entire myeloid lineage. For example, TGF-b
promotion of apoptosis. JunB-mediated growth arrest and cell deathand IL-6 have been reported to be potent activators of
could involve the downregulation (#) or upregulation (") of the poten-junB transcription (Jonk et al., 1998; Sjin et al., 1999)
tial target genes. The lineage diagram has been adapted from Akashi
and Smad3/Smad4 have been found to interact with et al. (2000). LT-HSC: long-term hematopoietic stem cell; ST-HSC:
JunB to regulate downstream events of the TGF-b sig- short-term hematopoietic stem cell; CMP: common myeloid progen-
itor; CLP: common lymphoid progenitor; GMP; granulocyte/macro-naling pathway (Liberati et al., 1999). Therefore, we can
phage progenitor; MEP: megakaryocyte/erythroid progenitor; GP:only speculate that the specificity of JunB function dur-
granulocyte progenitor; MP: macrophage progenitor; McP: pre-ing late granulopoiesis is due to its selective activation in
sumptive mast cell progenitor.subsets of myeloid cells rather than in the entire lineage.
Further characterization of JunB-deficient granulo-
cyte progenitors reveals prolonged survival and in- inhibitor p16 (Passegue´ and Wagner, 2000). In granulo-
creased responsiveness to GM-CSF-mediated prolifera- cyte progenitors, the absence of JunB results in a down-
tion demonstrating thereby that JunB normally controls regulation of p16 expression but also in increased levels
the numbers of granulocyte progenitors by inhibiting of c-Jun, a potent activator of cell proliferation that regu-
proliferation and promoting apoptosis (see Figure 7). lates the p53 pathway (Schreiber et al., 1999). Hence,
Increased responsiveness to GM-CSF could be a central
changes in the expression levels of different cell cycle
mechanism in leukemogenesis. Previous studies have
regulators could also contribute to the increased prolif-
implicated elevated levels of GM-CSF or deregulated
eration of JunB-deficient granulocyte progenitors.
GM-CSF receptor signaling in aberrant myeloid prolifer-
Impaired apoptosis has also been shown to contributeation. Hence, overexpression of GM-CSF in mice in-
to myeloid leukemogenesis. Constitutive Bcl2 overex-duces a fatal myeloproliferative disease (Johnson et al.,
pression in mature granulocytes in the hMRP8-bcl21989), while GM-CSF-deficient mice display normal he-
transgenic mice inhibits apoptosis in vitro but is notmatopoiesis (Dranoff and Mulligan, 1994). Furthermore,
sufficient to alter myeloid homeostasis in vivo (Lagassetransgenic mice expressing the activated b(c) common
and Weissman, 1994), while additional inactivation ofsubunit of the GM-CSF receptor also develop myeloid
the Fas pathway predisposes to the development ofhyperplasia and splenomegaly (D’Andrea et al., 1998).
acute myeloid leukemia (Traver et al., 1998). Therefore,Although the levels of circulating GM-CSF are not
the upregulation of Bcl2 and of the related family mem-changed in junB2/2Ubi-junB mice (data not shown), the
ber Bclxl observed in JunB-deficient granulocyte pro-JunB-deficient granulocyte progenitors display elevated
genitors are likely to contribute to the extended survival.expression of the specific a subunit of the GM-CSF
Upregulation of Bclxl is most probably an indirect conse-receptor. Increased expression of the receptor and/or
quence of the increased GM-CSF responsiveness sinceincreased signaling through the GM-CSF receptor path-
Bclxl is a known target of the GM-CSF receptor/STAT5way may therefore be causal to the observed myelopro-
signaling pathway in the myeloid lineage (Kieslinger etliferative disease. Interestingly, JunB-deficient granulo-
al., 2000). Preliminary results suggest that JunB maycytes also display elevated levels of c-Jun and have
directly downregulate Bcl2 expression since Bcl2 pro-increased expression of the M-CSF receptor. Since
tein levels are elevated in junB2/2 fibroblasts and re-c-Jun has recently been shown to act as a coactivator
duced in JunB-overexpressing fibroblasts (data notof Pu.1 in regulating M-CSF receptor expression (Behre
shown). Future studies with the promoters of these anti-et al., 1999), it is possible that such an indirect syner-
apoptotic genes will determine how JunB regulates theirgistic regulation applies not only to the M-CSF receptor,
expression.but also to other growth factor receptors like the GM-
Additional evidence for a central role of JunB in con-CSF receptor. On the other hand, JunB has been shown
trolling myeloid differentiation comes from the resultsto be a negative regulator of fibroblast proliferation act-
ing mainly through transcriptional activation of the CDK obtained with bone marrow–derived mast cell lines. Es-
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and TPO (5 ng/ml). EBs-derived hematopoietic colonies were ana-tablished JunB-deficient mast cells exhibit an immature
lyzed after 13 and 15 days of secondary differentiation. For colony-and highly proliferative phenotype, which can be fully
forming assays, primary bone marrow and spleen cells (1 3 105)reverted by ectopic JunB expression. In contrast, resto-
were plated in 1% IMDM-based methylcellulose media supple-
ration of p16 levels, which are also reduced in JunB- mented with 10% FCS, SCF (1:500), IL-3 (1:500), GM-CSF (2 ng/ml),
deficient mast cells, downregulates proliferation, but is and G-CSF (10 ng/ml) together (Mix conditions) or separately. The
number of GM-CFU per dish was scored after 7-day of differentia-not sufficient to induce differentiation and instead
tion. To derive mast cells, single colonies were isolated from bonecauses cell death. These findings clearly indicate that
marrow–derived 7 days methylcellulose cultures and expanded inJunB regulates the expression of multiple effector genes
serum-free StemPro-34 medium (GIBCO/BRL) supplemented withwhich are important for cell proliferation, differentiation,
SCF (1:500) and IL-3 (1:500) with medium replenished every 3 days
and survival during myelopoiesis. and split 1:10 every 10 days. For infection experiments, cells were
Previous studies in fibroblasts have already shown cocultured for 3 days with GP1E86 packaging cells producing high
titers of viruses expressing the mouse junB cDNA (Matsuo et al.,that JunB may act as an anti-oncogene due to its nega-
2000) or the human p16 cDNA (gift from G. Peters, ICRF, London),tive regulatory function on cell proliferation (Passegue´
and recovered mast cells were grown for 6 days with or without 2.5and Wagner, 2000). The finding that JunB-deficient gran-
mg/ml puromycin.ulocyte progenitors display deregulated apoptosis sug-
gests that JunB may also be part of a pro-apoptotic
Cell Transferspathway. Finally, the fact that absence of JunB leads to
Bone marrow cells (2 3 106 cells in 400 ml PBS) were injected into
a myeloid leukemia, arising from increased proliferation the tail vein of 9.6 Gy lethally irradiated recipient mice (C57Bl/6 or
and decreased apoptosis, provides a clear demonstra- 129/svxC57Bl/6 F1 generation; 12- to 13-week-old). Control and
tion that JunB can act as a tumor suppressor gene in junB2/2 E12.5 fetuses were generated by injection of junB1/1 and
junB2/2 ES cells, respectively, into tetraploid wild-type blastocystsmice. Future experiments will determine whether the
as described (Wang et al., 1997). Each isolated E12.5 fetal liver wastumor suppressive function of JunB can be extended
homogenized in 400 ml IMDM medium and injected into the tail veinto human leukemia, mainly CML. A number of transgenic
of a single 9.6 Gy lethally irradiated recipient mouse (129/sv; 12- to
mouse models for human CML have already been gener- 13-week-old).
ated, but most of them result in acute leukemia (Heister-
kamp et al., 1990; Traver et al., 1998) or lack disease
Flow Cytometry
progression to blast crisis (Helgason et al., 1998). Only Cells were resuspended at 1 3 106 per 100 ml of PBS containing
very few recapitulate the natural course of the human 1% FCS and 10 mg/ml of purified mouse Fcg III/II receptor antibody
and stained for 30 min at 48C with the indicated mouse antibodiesdisease, such as knockout mice for the signaling mole-
(PharMingen). Viable cells, gated by light scatter and exclusion ofcules ICSBP (Holtschke et al., 1996) and Nf-1 (Largaes-
propidium iodide (1 mg/ml), were analyzed or sorted using a Cell-pada et al., 1996), but lack transplantablility during the
Quest software on a FACS Vantage machine (Becton Dickinson).myeloproliferative phase. Therefore, the junB2/2Ubi-
For DNA content analysis, Gr-1/Mac-1 stained splenocytes were
junB mice may provide a unique tool for the identification fixed overnight in the dark in 2% paraformaldehyde in PBS (50:50),
of genes contributing to both the myeloproliferative dis- washed twice in PBS/0.05% Tween-20, and resuspended in 500 ml
of PBS/0.05% Tween-20 containing 1 mg/ml propidium iodide beforeease and the progression to blast crisis, and ultimately
FACS analysis.to design effective therapies to interfere with these mo-
lecular events.
Proliferation and Apoptosis Assays
Primary splenocytes were resuspended in IMDM containing 10%Experimental Procedures
FCS and cultivated for 2 hr in tissue culture flasks to remove adher-
ent cells, including macrophages. Floating cells were harvested,Mice and Growth Factors
purified on a ficoll gradient, and mononucleated cells were thenJunB2/2Ubi-junB mice were generated as described (Schorpp-
either directly analyzed for apoptosis levels or cultivated for anKistner et al., 1999). All mice were in a mixed 129/svxC57Bl/
additional 72 hr. When indicated, the culture medium was supple-6xMF1xHimOF1 genetic background. Mouse SCF and IL-3 were
mented with SCF (1:500), IL-3 (1:500), GM-CSF (2 ng/ml or indicatedobtained as conditioned medium. Recombinant mouse GM-CSF,
amounts), and G-CSF (10 ng/ml). For proliferation assays, 2.5 3 104G-CSF, IL-11, TPO, and GM-CSF neutralizing antibody were pur-
cells were seeded per well of a 96-well plate, grown for 72 hr, andchased from R&D Systems and recombinant human EPO from Jans-
then pulsed for 2 hr with 1 mCi of 3H-thymidine/well. Cultures weresen-Cilag.
subsequently harvested and analyzed for 3H-thymidine incorpora-
tion by standard procedures. For apoptosis assays, 0.5 3 106 cellsHistological Methods
were seeded per well of a 6-well plate, grown for 72 hr, and thenTissues were fixed in 4% formaldehyde/PBS, paraffin-embedded,
processed for Gr-1/AnnexinV double staining as described (Liu etsectioned, and stained with hematoxylin-eosin. CAE (Sigma) and
al., 1996).MPO (DAKO) staining were performed according to the manufactur-
er’s instructions. For cytospin preparations, 5 3 105 cells were cyto-
centrifuged onto glass slides and stained with May-Gru¨nwald and RT-PCR and Western Blot Analysis
Giemsa solutions (Fluka). Blood was obtained from the tail vein and Total RNA was isolated using Trizol reagent (GIBCO/BRL). For all
blood counts were determined using an automated cell counter RT-PCR analyses, 1 mg total RNA was digested with DNase I to
(SYSMEX K-1000; TAO Medical Electronics). remove DNA contamination and reverse-transcribed according to
the manufacturer’s instructions (SuperScript IIe kit, GIBCO/BRL).
PCR amplifications were performed under standard conditions andIn Vitro ES Cell Differentiation, Colony-Forming Assay,
and Mast Cell Derivation each PCR product was electrophoresed on 2% NuSieve agarose
gels in 1X TAE, stained with ethidium bromide, and photographed.D3-derived junB1/2 and junB2/2 ES cells (Schorpp-Kistner et al.,
1999) were differentiated in vitro as described (Keller et al., 1993). Each gene was analyzed using specific primer pairs (sequence avail-
able upon request). Protein extracts and Western blot analyses wereEBs were harvested after 6 days from primary cultures, dissociated,
and 1 3 105 cells were replated in 1% IMDM-based methylcellulose performed according to standard procedures using 10 mg of whole
cell extracts. The JunB antibody was a generous gift from M. Yanivmedium supplemented with 10% FCS, SCF (1:500), IL-3 (1:500), GM-
CSF (3 ng/ml), G-CSF (30 ng/ml), IL-11 (25 ng/ml), EPO (8 U/ml), (Pasteur Institute, Paris), the Bcl2 antibody was obtained from Santa-
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Cruz, the Bclxl and c-Jun antibodies from Transduction Laboratory, Johnson, G.R., Gonda, T.J., Metcalf, D., Hariharan, I.K., and Cory,
S. (1989). A lethal myeloproliferative syndrome in mice transplantedand the actin antibody from Sigma.
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